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E-mail address: r-kolesnick@ski.mskcc.org (R. KoleRecent evidence suggests that ceramide regulates stress signaling via reorganization of the plasma
membrane. The focus of this review will be to discuss the mechanism by which acid sphingomyeli-
nase (ASMase)-generated ceramide initiates transmembrane signaling in the plasma membrane
exoplasmic leaﬂet. In particular, we review the unique biophysical properties of ceramide that ren-
der it proﬁcient in formation of signaling domains termed ceramide-rich platforms (CRPs), and the
role of CRPs in the pathophysiology of various diseases. The biomedical signiﬁcance of CRPs makes
these structures an attractive therapeutic target.
 2010 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Two decades ago, based on the proposal that sphingolipids may
be bioeffector molecules [1], our laboratory proposed the existence
of a signaling pathway initiated by hydrolysis of sphingomyelin
(SM) to ceramide by the action of a sphingomyelinase (SMase)
[2–4]. While initial studies conceived of a pathway similar in con-
cept to that of the phosphoinositide pathway where ceramide
served exclusively as a second messenger stoichiometrically acti-
vating protein targets to confer transmembrane signaling, experi-
ments from a number of biophysical laboratories began to alter
the perception of how this system might function. Speciﬁcally,
studies in model membranes showed that ceramide generation
changes membrane structure, leading to formation of macrodo-
mains [5,6], concepts adapted for eukaryotes over the past decade
[7]. This review details the capability of ceramide to reorganize
membranes based on its unique biophysical properties, linking
its biological and biomedical functions.
2. Ceramide: biology and biophysics
Ceramide is an evolutionarily conserved second messenger that
plays a ubiquitous, conserved role in biologic processes as diverse
as apoptosis, growth arrest, senescence and differentiation [8–12].
Ceramide is an N-acylsphingosine consisting of a fatty acid bound
to the amino group of the sphingoid base, sphingosine. In nature,
ceramides are usually found with monounsaturated or saturatedon behalf of the Federation of Euro
snick).fatty acids of various lengths from 2 to 28 carbon atoms, that
sometimes contain a hydroxyl group on either the C-2 position
(a-hydroxyceramide) or on the terminal carbon atom (x-hydroxy-
ceramide) [13]. The fatty acid chain length signiﬁcantly alters the
physical properties of ceramide [14,15]. Ceramides with fatty acyl
chains of 12 carbons or longer, i.e. long-chain ceramides, belong to
the category of ‘‘non-swelling amphiphiles”, as they cannot give
rise to micelles or other aggregates in aqueous suspension, and
hence cannot serve as detergents [16]. Alternatively, short-chain
ceramides swell in water, a property that limits their utility in re-
search. The most commonly-found mammalian ceramides in cellu-
lar membranes contain fatty acyl chains of 16–24 carbon atoms,
and are among the least polar and most hydrophobic of membrane
lipids. While free ceramides are found in abundance in skin stra-
tum corneum, rendering impermeability to this barrier, these cera-
mides often contain free fatty acids of extraordinary length and
unusual structure [13,17,18].
Depending on cell type and stimulus, ceramide can be gener-
ated either through sphingomyelinase (SMase)-dependent catabo-
lism of sphingomyelin (SM), a de novo synthetic pathway, a
salvage synthetic pathway, or at times through other cell-type spe-
ciﬁc mechanisms. SMase is a specialized form of phospholipase C,
which cleaves the phosphodiester bond of SM, generating cera-
mide. Several SMase isoforms exist and are distinguishable by their
pH optima, ion dependence and subcellular localization. SMases
are classiﬁed in three main groups – acid SMase (ASMase), neutral
SMase (NSMase), and alkaline SMase (Alk-SMase) [19]. While
ASMase and NSMase were long believed to be the only two forms
of SMase involved in signal transduction, new reports suggest
potential signaling roles for Alk-SMase [20]. SMase-mediatedpean Biochemical Societies.
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the plasma membrane, however ceramide may also be generated
in a more prolonged fashion via de novo synthesis, exclusively
intracellularly within the endoplasmic reticulum (ER) or mitochon-
drial-associated membrane (MAM) [21–24]. De novo ceramide bio-
synthesis is regulated by ceramide synthase gene products which
N-acylate sphinganine to form dihydroceramide, which is subse-
quently converted to ceramide by a desaturase [25]. In mammals,
six isoforms of ceramide synthase have been identiﬁed, each dis-
playing a high speciﬁcity toward acyl CoAs of different carbon
backbone lengths, hence synthesizing ceramides of distinct chain
lengths [26]. Findings in the recent years identiﬁed a novel mech-
anism of ceramide accumulation from the catabolism of complex
sphingolipids that are eventually broken down into sphingosine,
which is then reused through re-acylation to produce ceramide.
This latter pathway has been referred to as either sphingolipid
recycling or the salvage pathway. It involves a number of key
enzymes that include ASMase, possibly glucocerebrosidase (acid-
b-glucosidase), ceramidases, and (dihydro)ceramide synthases
(for review of this topic see [27]). Finally, hydrolysis of gangliosides
at the plasmamembrane might also contribute to the generation of
ceramide signaling in some systems [28].
As a second messenger, ceramide plays a ubiquitous role in di-
verse biologic processes [19,29]. While the exact mechanism by
which ceramide performs its biologic functions is not completely
understood, ﬁndings in the last decade suggest that changes in lo-
cal membrane structure induced by ceramide accumulation are
essential for its biologic function. A better understanding of cera-
mide’s effect on model and biologic membranes has been provided
by a number of biophysical research groups, summarized below.
Due to those properties, ceramides mix poorly with phospholipid
monolayers or bilayers, segregating into distinct, high-temperature
melting ceramide-enriched domains. In this review, we focus on
four properties of ceramide that mediate its function: its ability
to induce an increase in molecular ordering and domain formation,
undergo lamellar phase destabilization and membrane fusion, con-
fer membrane permeabilization, and facilitate transbilayer lipid
movement.
2.1. Lipid order and domain formation
Within lipid membranes, an increase in ceramide content re-
sults in increase in lipid order as determined by diphenylhexatri-
ene (DPH) polarization and NMR spectroscopy. DPH, a
ﬂuorescence probe, routinely used to study lipid chain order, in-
creases in ﬂuorescence yield with increasing molecular order. Uti-
lizing this method, Holopainen et al. showed that both natural
ceramides and chemically-deﬁned C16-ceramide lead to dose-
dependent increase in lipid acyl chain order of dim-
yristoylphosphatidylcholine and 1-palmitoyl-2-oleoyl phosphati-
dylcholine (POPC) bilayers, respectively [30,31]. Moreover, in situ
ceramide generation by SMase action upon SM/phosphatidylcho-
line (PC) bilayers leads to increased DPH polarization [31]. These
ﬁndings were conﬁrmed by Massey et al. who demonstrated that
increasing ceramide concentration increased DPH polarization in
dipalmitoylphosphatidylcholine (DPPC)/POPC/SM bilayers, ulti-
mately increasing the gel–ﬂuid phase transition temperature
[32]. Similarly, 2H-NMR spectroscopy studies demonstrated that
both bovine brain ceramide and synthetic C16-ceramide lead to
large increases in acyl chain order parameters of fully deuterated
ﬂuid state d62-DPPC and d31-POPC [33–35]. These studies also
showed that ordering of ceramide chains was greater than that
of phospholipids, such as POPC [33–35].
Ceramide-induced increase in lipid order in phospholipid bilay-
ers ultimately leads to lateral phase separation and formation of
ceramide-enriched domains, as initially demonstrated by H2NMR studies. These studies showed that ceramide addition induces
lateral phase separation of ﬂuid phospholipid bilayers into regions
of gel and liquid phases, with ceramide partitioning into the gel
phase [34,35]. Furthermore, these domains were detected by
Holopainen et al. in PC membranes using a pyrene-labeled
phospholipid (1-palmitoyl-2[(pyren-1-yl)]decanoyl-sn-glycero-3-
phosphocholine), a ﬂuorescence probe sensitive to lateral mobility
[31]. Similarly, differential scanning calorimetry and infrared spec-
troscopy studies demonstrated that in the lamellar phase, cera-
mides do not mix well with phospholipids, segregating into high-
temperature melting ceramide-enriched domains [36]. In fact a
small increase in ceramide levels can signiﬁcantly affect mem-
brane properties, as demonstrated by ﬂuorescent spectroscopy
and transmission electron microscopy (TEM) studies of C16-cera-
mide/POPC bilayers, where at concentration as low as 2 mol% cer-
amide strongly affects POPC ﬂuid matrix [37].
Ceramide-enriched domains in SM/ceramide vesicle bilayers
were described by Sot et al. [38]. Giant unilamellar vesicles (GUVs)
composed of SM and egg ceramide were doped with ﬂuorescent
DiIC18, a probe that partitions preferentially into more ﬂuid mem-
brane regions. Fluorescence microscopy analysis indicated that
while pure SM vesicles appear uniformly stained, those containing
egg ceramide displayed dark areas corresponding to rigid, cera-
mide-rich domains at as low as 5 mol% ceramide. Increasing cera-
mide concentration further increased the dark areas, and caused a
shape change from circular to elongated eventually leading to coa-
lesce of these domains into a single continuous domain [38].
Since in biologic systems and in particular during apoptotic
signaling, membrane ceramide is generated via SMase-catalyzed
cleavage of the phosphodiester bond of SM, a number of biophys-
ical studies of domain formation were performed in ceramide/SM
mixtures to show that ceramide generated in situ by SMase segre-
gates laterally in the same way as natural or synthetic ceramide
added exogenously. Holopainen et al. ﬁrst observed that addition
of bacterial SMase to SM-containing vesicles changes lateral mem-
brane organization, forming detectable ceramide-rich domains by
ﬂuorescence spectroscopy [31]. Subsequently, Nurminen et al.
showed that contacting SMase-tethered amino-derivatized acry-
late microspheres to GUVs containing ﬂuorescent Bodipy(Bdp)-la-
beled SM leads to formation of ceramide-rich domains. As
observed by ﬂuorescence microscopy, ceramide generation reorga-
nized GUV membrane, with Bdp-labeled ceramide molecules accu-
mulating at one pole of the GUV, whereas prior to ceramide
generation Bdp-labeled SM was homogeneously distributed across
the membrane (Fig. 1) [39].
In situ ceramide generation by SMase action in model mem-
branes of biologic relevance was further examined by combining
ﬂuorescence and atomic force microscopy (AFM). These studies
showed that in situ ceramide formation leads to changes in height
and shape of lipid domains in equimolar DOPC/SM/cholesterol sup-
ported bilayers, as well as in bilayers containing protruding SM/
cholesterol-rich domains that mimic lipid rafts [40–42]. In fact,
studies by Ira and Johnson provided direct visualization of cera-
mide-induced clustering of small nanometer-sized domains into
large ordered domains with diameters as large as 1 lm. Many of
these domains were raised 2 nm above the surface of the mem-
brane, likely caused by formation of ceramide in the upper mem-
brane leaﬂet. Alternately, high ceramide concentration in the
lower leaﬂet resulted in negative membrane curvature, discussed
in the following sections [41–43].
2.2. Non-lamellar phase transition, membrane fusion and ﬁssion
Ceramide facilitates transition from a lamellar to non-lamellar
membrane phase, more speciﬁcally to an inverted hexagonal
phase, in model phospholipid membranes as demonstrated by
Fig. 1. Ceramide-rich platform formation in a model membrane. Still ﬂuorescent microscopy images depicting membrane reorganization of SOPC:C16-0 SM:Bdp-SM
(0:75:0.2:0.05) GUV (A) following ceramide formation by SMase coupled onto amino-derivatized acrylate (B–F). Contacting membrane surface with immobilized SMase (B)
resulted in generation of ceramide patches in one pole of the GUV depicted at 45 min (C), 50 min (D), 55 min (E) and 90 min (F). Adapted from Nurminen et al. [39].
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scattering [15,36,44]. The ability of ceramide to stabilize inverted
phases has been attributed to its geometry, as ceramides, unlike
most other lipids, have a small headgroup, easily accommodated
into non-lamellar phases [45]. This property has been subse-
quently linked to ceramide’s ability to facilitate membrane curva-
ture leading to fusion and ﬁssion [45,46]. Currently, the most
widely-accepted mechanism for membrane fusion involves tran-
sient participation of a non-lamellar structure, the ‘‘stalk”, a
semitoroidal structure that allows merger of apposed membrane
leaﬂets. Due to its ability to promote non-lamellar phase stabiliza-
tion, ceramide can similarly facilitate stalk formation [6,47].
Effects of ceramide on membrane fusion were ﬁrst demon-
strated by Ruiz-Arguello in large unilamellar vesicles (LUVs) con-
taining SM, phosphatidylethanolamine (PE) and cholesterol.
SMase treatment of these vesicles led to ceramide generation in
seconds accompanied by vesicle aggregation, indicated by cryo-
transition or TEM. Further, addition of ceramide at 5–10 mol% in
PC-containing vesicles reduced the time required for fusion of
smaller vesicles in response to addition of phospholipase C
[44,48]. Similar to fusion, ceramide-induced budding of vesicles,
i.e. ﬁssion, was demonstrated following addition of SMase by
microinjection or coupled to amino-derivatized acrylate micro-
spheres to PC/SM and SM GUVs, respectively. SMase-induced SM
cleavage and ceramide generation resulted in shedding of small
membrane vesicles into the GUV interior, visualized by ﬂuores-
cence microscopy [39,49]. The authors attributed this phenomenon
to the tendency of ceramide to separate into domains, induce neg-
ative spontaneous curvature and the augmented bending rigidity
of the ceramide-enriched domains, leading to bilayer invagination
and vesiculation.
Biologic signiﬁcance of the biophysical ﬁndings conﬁrming
fusagenic properties of ceramide was demonstrated in ATP-de-
pleted macrophages and ﬁbroblasts. Although ATP hydrolysis hasbeen regarded as a general requirement for internalization pro-
cesses in mammalian cells, treatment of ATP-depleted macro-
phages and ﬁbroblasts with exogenous SMase rapidly induced
formation of numerous vesicles, approximately 400 nm in diame-
ter, not enriched in clathrin or caveolin, that pinched off from plas-
ma membrane into cytoplasm [50]. The authors hypothesized that
the reason that SMase activity and ceramide formation override
the requirement for ATP hydrolysis in the process of vesicular for-
mation lies in the ability of ceramide to cause negative curvature,
as demonstrated by Helfritch et al. [45]. High ceramide concentra-
tions would in turn lead to vesicle ﬁssion by the mirror image of
their facilitation of fusion [36]. Ceramide-induced vesicle fusion
was also demonstrated in a cellular system, sea urchin cortical ves-
icles treated with SMase [51]. Finally, ability of ceramide to induce
membrane curvature, leading to fusion and ﬁssion, may have an
important function in pathogenic infections, which will be de-
scribed in more detail in subsequent sections of this review. ASM-
ase has been shown to be obligatory for internalization of a
number of pathogens, as well as a subsequent intracellular im-
mune response, early stages of which are mediated by fusion of
intracellular phagosome with lysosome leading to pathogen erad-
ication [52].
2.3. Membrane permeability
Ceramide-induced membrane permeability was initially dem-
onstrated in model membranes by Ruiz-Arguello et al. The authors
used LUVs composed of SM, PE and cholesterol that contained an
entrapped ﬂuorescent dye solution [44]. SMase treatment induced
ceramide formation and leakage of intravesicular aqueous content.
This effect, independent of the speciﬁc lipid composition of the
LUV or the type of the dye entrapped, was also observed in ﬂuores-
cent dye loaded and resealed erythrocyte ghosts after SMase addi-
tion. These ﬁndings were conﬁrmed by Montes et al. in LUVs
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Bacillus SMase or long-chain ceramides released dextrans of molec-
ular mass of 20 kDa [53].
Physiologic relevance of ceramide-induced membrane perme-
ability was suggested by studies of Siskind and Colombini. Using
electrophysiologic detection methods, the authors provided evi-
dence that ceramide forms channels in isolated mitochondria lead-
ing to increased permeability of mitochondrial outer membranes
to cytochrome c and other small proteins [54,55]. An additional as-
pect of these studies, strengthening the argument that ceramide-
induced increase in membrane permeability mediates apoptosis
induction following certain stimuli, is the demonstration that dihy-
droceramide, which is inactive in promoting apoptosis at the cellu-
lar level, has minimal permeabilizing activity in planar lipid
bilayers, and in fact inhibits mitochondrial permeabilization by
ceramides [55,159]. Recent evidence by Siskind et al. reveals the
relationship between ceramide channels in mitochondria and Bcl-2
family members, key regulators of mitochondria-mediated apopto-
sis. These studies showed that anti-apoptotic proteins, Bcl-xL and
Bcl-2, disassemble ceramide channels in the mitochondrial outer
membranes of isolated mitochondria from rat liver and yeast, sug-
gesting ceramide channels as one mechanism for releasing pro-
apoptotic proteins from mitochondria during the induction phase
of apoptosis [56].
While a mechanism for ceramide-induced increase in perme-
ability has not yet been elucidated, this phenomenon was attrib-
uted to ceramide’s molecular structure and its preference for
domain formation and transmembrane movement [6]. Colombini
and co-workers postulated a model of a ceramide pore consisting
of columns of four to six ceramide molecules linked by hydrogen
bonds via amide groups and arranged as parallel or anti-parallel
staves [57]. Since addition or generation of ceramide in situ is re-
quired to induce leakage, it has been suggested that the process
of generation of microdomains rich in ceramide within the disor-
dered sea of lipids induces membrane leakage at the interfaces be-
tween ceramide-rich and poor domains [58]. Additionally, the
ability of ceramide to undergo ‘‘ﬂip-ﬂop” diffusion (described be-
low), leading to transbilayer lipid movement, could lead to discon-
tinuities in the membrane permeability barrier [6].
2.4. ‘‘Flip-ﬂop” transbilayer diffusion
Spontaneous transbilayer movement of ceramide has been
demonstrated in lipid vesicles and cell membranes. Kinetic studies
of ‘‘ﬂip-ﬂop” movement of a ﬂuorescent analog of ceramide in
POPC vesicles by Bai and Pagano reported that ceramide has a con-
siderably faster ﬂip-ﬂop rate than phospholipids [59]. Lopez-Mon-
tero et al. subsequently showed that incorporation of a small
percentage of ceramide into the external leaﬂet of egg PC GUVs
leads to a reversible shape change from prolate to pear-shaped.
The reversibility of the shape change implied transmembrane
movement of lipids, more speciﬁcally ceramide, which was con-
ﬁrmed with spin-labeled ceramide analog incorporated into LUVs
[60]. Additional studies demonstrated ceramide ‘‘ﬂip-ﬂop” in mod-
el and cellular (i.e. LUVs and erythrocyte ghost, respectively) mem-
branes following ceramide generation in situ [61]. When GM3 was
limited to the outer leaﬂet of neuramidase-containing SM/PE/cho-
lesterol LUVs, Contreras et al. demonstrated that external addition
of SMase caused GM3 hydrolysis. The most parsimonious explana-
tion of these data is that ceramide generation in the outer leaﬂet
promoted lipid exchange with the inner leaﬂet, thus permitting
GM3 access to the entrapped neuramidase [61]. In a parallel study,
a preparation of SM-containing liposomes or erythrocyte ghosts
was labeled with a ﬂuorescent energy donor NBD-PE in the inner
leaﬂet. Addition of SMase to hydrolyze SM to ceramide was accom-
panied by ﬂuorescence energy transfer to an impermeable acceptorin the outer aqueous medium, suggesting the NBD-PE ﬂipped to
the outer monolayer [61]. Similar effects were observed when
egg ceramide, but not dihydroceramide, was added externally to
pre-formed vesicles [62].
The suggested reasons for the ceramide-induced transbilayer li-
pid movements are twofold [6]. The ﬁrst is ceramide’s property to
facilitate lamellar to non-lamellar phase transition, mentioned
above. The idea is that formation of ceramide on one side of the
membrane would induce the transient formation of non-lamellar
structural intermediates, leading to loss of membrane bilayer
asymmetry, mixing of surrounding lipids, and as the structure col-
lapses transbilayer lipid exchange. The second reason was attrib-
uted to general membrane properties, such as a tendency for
mass conservation in each membrane leaﬂet. When one membrane
layer becomes enriched with ceramides, they diffuse towards the
other leaﬂet, leading to movement of non-ceramide lipids in the
opposite direction so that the net mass transfer between monolay-
ers is avoided. The observation of the ﬂip-ﬂop movement of cera-
mide between membranes would appear particularly relevant to
its biologic effects in mammalian cells, especially in the SMase sig-
naling pathway. SMase-catalyzed SM hydrolysis and ceramide for-
mation occur on the outer plasma membrane because most
mammalian SM is found on the exoplasmic leaﬂet of the plasma
membrane. Spontaneous transbilayer movement of ceramide is
hence necessary for its interaction with intracellular targets. The
following section attempts to describe the biologic effects of cera-
mide in mammalian membranes in terms of the biophysical
parameters described above.
3. Ceramide-rich platforms
ASMase-mediated ceramide generation on the exoplasmic leaf-
let of the plasma membrane alters membrane structure with sub-
stantive consequence for transmembrane signaling. The unique
biophysical properties of ceramide, described in the previous sec-
tion, such as its preferential self-association and ability to act as
a fusagen, mediate formation of ceramide-rich platforms (CRPs)
with diameters of 200 nm up to several microns. These macrodo-
mains can be visualized by a variety of techniques including scan-
ning electron microscopy, and conventional and confocal
ﬂuorescence microscopy, as depicted in Fig. 2 [63]. CRPs appear
to be sites of protein oligomerization for the purpose of transmem-
brane signaling, reviewed below. While recent evidence indicates
that NSMase, and perhaps even Alk-SMase may be involved in
transmembrane signaling, far less is known about signaling via
these two enzymes than via ASMase. Hence, the remainder of this
review will focus on ASMase-initiated signaling at the plasma
membrane.
3.1. Biology of ASMase
While ASMase was originally considered strictly lysosomal be-
cause of its pH optimum at 4.5–5.0, Liu and Anderson observed
ASMase localization within secretory vesicles at the plasma mem-
brane [64]. Subsequent studies determined that the enzyme exists
in two forms, termed lysosomal SMase (L-ASMase) and secretory
SMase (S-ASMase), differing in glycosylation pattern and NH2-ter-
minal processing, and consequently in subcellular targeting. Con-
trary to original belief, Schissel et al. determined that because
only the on and off rate of the substrate, rather than the catalytic
activity of the enzyme, is regulated by pH, ASMase can also hydro-
lyze SM at the neutral pH found at the cell surface, albeit with low-
er efﬁciency [24].
L-ASMase and S-ASMase are derived from the same gene and
698 amino acid protein precursor, as ﬁrst demonstrated by Sand-
hoff and co-workers [65]. Using pulse-chase metabolic labeling,
Fig. 2. Ceramide-rich platforms in murine tracheal epithelial cells following in vivo infection with Pseudomonas aeruginosa. Fluorescence microscopy images demonstrate
colocalization of surface ceramide with P. aeruginosa and ASMase on the cilia of in vivo-infected murine tracheal epithelial cells at 20 min post infection. Adapted from
Grassme et al. [94].
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a common primary translation product of 75 kDa (preproform),
converted into 72 kDa precursor (proform) in the ER/Golgi com-
plex. Soon after entry into the ER, the N-terminal signal sequence
(amino acids 1–46) is removed by a signal peptidase. Several addi-
tional residues following the signal sequence are also removed, as
recombinant human mature ASMase was reported to contain 570
amino acids, pointing to a loss of the ﬁrst 59 amino acids in total.
In fact, the N-terminal amino acid sequence analysis reported by
Tabas and co-workers revealed that ASMase isolated from the lyso-
somal fraction of CHO cells began with Gly66, whereas S-ASMase
puriﬁed from conditioned media of these cells contained an addi-
tional 6 amino acids and began with His60 [66]. Sandhoff and co-
workers reported additional N-terminal processing of L-ASMase
that was isolated from human placenta. N-Terminal sequencing
of this particular enzyme determined that Gly83 was the ﬁrst ami-
no acid [67]. These data collectively explain the more rapid migra-
tion of L-ASMase than S-ASMase on SDS–PAGE, which is due both
to additional N-terminal proteolytic processing of L-ASMase and
differences in the oligosaccharide proﬁle between the two enzyme
forms. Glycosylation of ASMase is thought to promote proper fold-
ing and trafﬁcking, as well as serve a protective role, preventing
destruction in the harsh environment of the lysosome. There are
six predicted N-glycosylation sites on the ASMase polypeptide
chain, of which ﬁve have been conﬁrmed. The differences in glyco-
sylation pattern between L-ASMase and S-ASMase are such that
while L-ASMase possesses a high mannose N-glycan composition,
and hence is sensitive to Endo H cleavage (Endo H cleaves Asn-
linked mannose rich oligosaccharides, but not highly processed
complex oligosaccharides), S-ASMase exhibits a complex type pat-
tern [66].
Following glycosylation, the mannosylated polypeptide precur-
sor enters either the lysosomal or secretory pathway. In the lyso-
somal pathway, ASMase undergoes modiﬁcation and trafﬁcking
which is typical for lysosomal proteins – acquisition of mannose-
6 phosphate residues by the sequential actions of N-acetyl
glucosamine-1-phosphotransferase and N-acetyl glucosamine
phosphodiesterase on mannose residues of the precursor. Vesicles
containing mannose–phosphate receptors then shuttle the modi-
ﬁed enzyme to the early endosome or late endosome/prelysosome.
In contrast, S-ASMase escapes the mannose-6 phosphate shuttle
and is directed into the secretory pathway [66].
Both forms of ASMase are metalloenzymes containing several
highly conserved Zn2+ binding motifs and are activated by Zn2+.
Unlike S-ASMase, L-ASMase is exposed to Zn2+ during trafﬁcking
to or within lysosomes (and/or during cellular homogenization),
and does not require addition of exogenous Zn2+ for in vitro activ-
ity. Studies by Tabas and co-workers conﬁrmed the prediction that
ASMase is exposed to and binds intracellular Zn2+ during trafﬁck-ing to lysosome by following endocytosis of highly puriﬁed se-
creted FLAG-tagged S-ASMase (which is Zn2+-dependent) in
ASMase null ﬁbroblasts [66]. Following 16 hour incubation, cata-
lytically active ASMase was detected in the lysosomes, where its
in vitro activity was not dependent on exogenously-added Zn2+.
In contrast, activity of ASMase that was not endocytosed was al-
most entirely Zn2+-dependent [66]. An exception to the Zn2+
requirement for in vitro activity of S-ASMase was observed in
endothelial cells, which are a particularly rich source of this form
of ASMase. S-ASMase from endothelial cells is not entirely depen-
dent on the exogenous addition of Zn2+, indicating that subcellular
localization of Zn2+ and the exposure of ASMase to its intracellular
stores might be subjected to cell type variation or regulation [68].
Activation of ASMase by various stimuli has been extensively
studied in the past decade. ASMase is activated via engagement
of the TNF-receptor superfamily members – Fas [69–71], CD40
[72], DR5 [73] and TNFa [74,75]. Further, a number of groups dem-
onstrated activation of ASMase by various stress stimuli, such as
LPS [76,77], disruption of integrin signaling [78], engagement of
the PAF-receptor [79], UV-light (UV-A [80] and UV-C [81–83]), heat
[84,85], oxidative stress [86], chemotherapeutic agents (cisplatin
[87], gemcitabine [88], doxorubicin [89], etoposide (Jacobi and
Haimovitz-Friedman, unpublished)), ionizing radiation (IR)
[90,91] and accumulation of Cu2+ [92]. Further, Neisseriae gonor-
rhoea [93], Pseudomonas aeruginosa [94], Staphylococcus aureus
[95], rhinovirus [96] and Sindbis virus [97] lead to ASMase activa-
tion, which is instrumental in pathogen internalization and host
cell response. Finally, receptors with various functions that medi-
ate differentiation, phagocytosis, regulation of cell adhesion or in-
duce inﬂammation, namely CD20 [98], interleukin-1 [99], CD5
[100], CD28 [101], LFA-1 [102] and FccRII [103] have also been
shown to activate ASMase.
Initial studies that demonstrated ASMase activation by cellular
stress were performed by Gulbins and co-workers who demon-
strated that Fas stimulation increases the Vmax of ASMase, accom-
panied by enzyme translocation onto the outer leaﬂet of plasma
membrane, bringing it into the proximity of its substrate, SM
[69,71,104,105]. While it has not been formally shown which form
of ASMase (or perhaps both) is the form involved in transmem-
brane signaling, by virtue of its location and cell-type preferential
expression, we believe that S-ASMase in most instances represents
the stress signaling form.
The mechanisms mediating surface translocation and activation
of ASMase are not well understood. Fas triggers this process by
recruitment of a small amount of the adaptor protein FADD and
initiator caspase 8 (see below for details). In this regard, mutation
of the Fas death domain, which mediates the interaction with the
adaptor protein FADD and with caspase 8, or genetic and pharma-
cologic inhibition of caspase 8, inhibit ASMase activation
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induced ASMase activation and ceramide generation is inhibited in
caspase inhibitor zVAD-treated or in caspase 8- or FADD-deﬁcient
cells, UV-C triggers these events independently of caspase activity
[82]. Furthermore, ASMase activation via the TNF-R55 does not
seem to be mediated by caspase 8, but rather by another unknown
initiator caspase [108]. These data suggest that several pathways
exist to initiate surface translocation and ASMase activation, even
in response to stimuli that lead to the same outcome.
Additional in vitro studies by Qui et al. demonstrated that oxi-
dation of cysteine 629 of ASMase leads to constitutive enzyme
activity [109]. Although not yet proven in vivo, it is an attractive
proposal since many stress stimuli known to activate ASMase in-
duce formation of oxygen radicals. In fact, Charruyer et al. showed
that UV-C irradiation results in redox-dependent activation and
translocation of ASMase to the outer leaﬂet of the plasma mem-
brane, ceramide generation and apoptosis [81]. Similarly, Dumitru
et al. demonstrated that TRAIL (TNF-related apoptosis-inducing li-
gand) induces rapid release of ROS prior to ASMase activation [73].
In this regard, the antioxidants Tiron or N-acetycysteine blocked
TRAIL-induced ASMase activation, ceramide generation and apop-
tosis in BJAB cells or splenocytes [73]. Finally, studies in a radiosen-
sitive human head and neck squamous carcinoma cell line (SCC61)
showed that IR induces ASMase translocation and activation, abol-
ished by ROS scavengers [110].
3.2. Structure of ceramide-rich platforms
CRP formation was ﬁrst described following stimulation of the
Fas receptor in Jurkat T and JY B lymphocytes [69,71]. The authors
demonstrated that Fas ligand (FasL) activates ASMase and signals
its translocation onto the extracellular leaﬂet of the plasma
membrane. Electron microscopy studies using nanogold-coupled
anti-ASMase antibody suggested that the enzyme localizes within
intracellular vesicles, mobilized upon Fas stimulation. These vesi-
cles subsequently fuse with plasma membrane exposing ASMase
on the outer leaﬂet bringing it into contact with its substrate SM
[69,104]. ASMase activation and translocation was detected within
minutes of Fas stimulation, leading to ceramide generation and
CRP formation within the same time frame. The mechanism of
Fas-induced CRP formation was thereafter shown operative in
many other cell types including SKW 6.4, JY B cell lymphoma, H9
T cell lymphoma, human peripheral blood lymphocytes, epithelial
and mouse granulose cells, lung epithelial cells, primary murine
splenocytes and hepatocytes, to list a few [111].
Because of the membrane localization of SM, CRPs are assumed
to be derived from rafts, liquid ordered microdomains within plas-
ma membrane, however deﬁnitive experimental proof for this
hypothesis has yet to be provided. SM is the main sphingolipid
component of plasma membrane and as much as 70% of SM is
found in the outer leaﬂet of plasma membrane. Sphingolipids have
signiﬁcantly higher melting temperature than other phospholipids
and interact with each other via hydrophilic interactions between
their head groups and hydrophobic interactions between their side
chains. Their molecules pack tightly in membranes due to their sat-
urated hydrocarbon chains, contrasting with unsaturated fatty acyl
chains of other phospholipids in the membrane. Interactions be-
tween sphingolipid molecules are additionally stabilized by cho-
lesterol, which ﬁlls void spaces by interacting with SM via
hydrogen bonds and hydrophobic van der Waals interactions of
the sterol ring system and SM’s ceramide moiety [112–114]. Tight
packing of sphingolipids, hydrophilic and hydrophobic interactions
between SM molecules, stabilized by cholesterol, lead to lateral
separation of these lipids from bulk phospholipids, resulting in
spontaneous formation of sphingolipid and cholesterol-enriched li-
quid ordered microdomains, termed rafts [114]. Treatment withdrugs that sequester or extract cholesterol from membrane, such
as b-cyclodextrin, ﬁlipin or nystatin, leads to disruption of these or-
dered domains, conﬁrming the stabilizing function of cholesterol
[115].
Translocation of ASMase appears targeted to rafts, as ﬂuores-
cence microcopy studies in Jurkat T lymphocytes demonstrated
that surface ASMase co-localizes with the raft marker GM1
[69,71,104]. Further, studies in model membranes showing that
cholesterol can modify the activity of ASMase provide an addi-
tional hint regarding the location of its plasma membrane activity
[24,116]. Contreras et al. showed that while ASMase is almost inac-
tive on LUVs without cholesterol, the addition of cholesterol results
in remarkable enhancement of enzyme activity [116].
3.3. Function of ceramide-rich platforms
Functionally, CRPs provide a platform to re-organize (and re-
compartmentalize) receptor and signaling molecules at the cell
membrane to facilitate ampliﬁcation of signaling processes. In par-
ticular, CRP formation sorts proteins on the cell surface, providing a
mechanism for spatial re-organization of receptors into clusters
upon cellular stimulation. Ultimately, high receptor density within
this small area of cell membrane, which seems prerequisite for sig-
nal transmission, facilitates downstream activation of molecules
that associate with the receptor. For example, in Fas signaling,
engagement of pre-trimerized Fas receptor activates within sec-
onds a small percentage (1–2% of maximum) of procaspase 8 and
the adaptor protein FADD, sufﬁcient for ASMase translocation
and CRP formation. CRPs in turn provide a platform for Fas oligo-
merization, which facilitates formation of the death-induced sig-
naling complex (DISC), an event essential for the other 98% of
Fas-induced FADD and Caspase 8 activation, and eventually apop-
tosis of these cells [106]. This ampliﬁcation function of CRPs in Fas
signaling was delineated in studies in B lymphocytes lacking func-
tional ASMase [69,71,104]. In contrast to wild-type cells, Fas stim-
ulation in ASMase null lymphocytes is unable to generate
ceramide, and in turn CRP formation is not observed. Subsequently,
deﬁciencies in DISC formation were detected. Weak recruitment of
FADD was accompanied by markedly attenuated activation of cas-
pase 8, reaching only 1% of the level achieved after maximal Fas
activation in wild-type cells, and abrogation of apoptosis. Addition
of nanomolar quantities of C16-ceramide directly initiated CRP for-
mation, in turn restoring Fas clustering and Fas-initiated signaling
of apoptosis in ASMase-deﬁcient cells. These studies showed that
following Fas stimulation, CRPs serve as signaling platforms that
cluster activated receptor molecules, providing a feed forward
mechanism that ultimately results in signiﬁcant ampliﬁcation of
a weak primary signal leading to a signal transduction cascade
[69,71,104].
Furthermore, CRPs could function as domains that recruit mol-
ecules transmitting the signal initiated by the receptor, as with Fas,
while at the same time exclude molecules that negatively interfere
with the signal that the receptor transmits. The mechanism, how-
ever, that mediates preferential partitioning or exclusion of pro-
teins into CRPs is still not understood. Studies by Bock et al.
provided initial insights into the molecular mechanism of receptor
clustering in CRPs following CD40 stimulation. The authors re-
placed the membrane-spanning region of CD40, known to localize
within CRPs following receptor stimulation, with the membrane-
spanning region of CD45, which localizes outside of rafts, at least
in some cells [117]. The studies revealed that while CD40 clustered
in CRPs following stimulation with CD40 ligand (CD40L), CD40/
CD45 chimeras were unable to cluster within these structures,
and in fact were excluded from CRPs. The mutant also failed to ini-
tiate signaling upon cellular stimulation, such as p38MAPK phos-
phorylation, typically observed in 3A9 T cell hybridoma after
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CD40/CD45 mutant was sufﬁcient to restore p38MAPK phosphory-
lation, conﬁrming the notion that CD40 clustering in membrane
platforms leads to signal ampliﬁcation. Further, these studies dem-
onstrated that, at least for CD40, the membrane-spanning region
determines preferential partitioning of proteins into CRPs [117].
Finally, by limiting lateral diffusion of proteins and lipids within
CRPs, these structures might serve as stabilizing platforms for
receptor–ligand interaction, inducing a change in receptor confor-
mation and increasing receptor afﬁnity for the ligand. The phe-
nomenon that receptor and ligand are immobilized within CRPs
has been shown for Fas/FasL and CD40/CD40L pairs [69,118,119].
Besides providing a signaling platform by clustering receptors
and amplifying a signal generated on the plasma membrane, CRPs
could also directly regulate protein function by interacting with
proteins on the cytoplasmic leaﬂet of the membrane. This function
of CRPs is enabled by a unique property of ceramide to spontane-
ously ﬂip to the cytoplasmic leaﬂet. Ceramide has been shown to
interact with and activate a number of proteins, namely phospho-
lipase A2, kinase suppressor of Ras (KSR), atypical protein kinase C
isoforms, c-Raf-1, Cathepsin D and ceramide-activating protein
phosphatases (CAPP) [120–124]. Whereas the exact mechanism
of ceramide-mediated regulation of most of these proteins remains
to be explored, recent evidence suggests that in at least some in-
stances interaction with ceramide targets proteins to CRPs [125].
As demonstrated by Yin et al., EGF stimulation induces transloca-
tion of KSR1 and its subsequent activation. Speciﬁcally, KSR binds
to and selectively trafﬁcs its substrate c-Raf-1 into CRPs, the sites
of c-Raf-1 activation. Mutations within the ceramide-binding do-
main of KSR-1, the atypical C1 domain, attenuate EGF-induced
KSR-1 membrane translocation, KSR-1 kinase activation and c-
Raf-1 mediated cell proliferation [125].
Additionally, rafts, caveolae and CRPs are employed by a wide
range of pathogens including bacteria, viruses and parasites to in-
fect mammalian cells. These structures have been implicated in
many aspects of infection, such as pathogen internalization, intra-
cellular maturation of phagosomes, lysis and fusion of phago-
somes, virus budding, immune receptor signaling and induction
of cell death upon infection and release of cytokines [126,127].
Speciﬁcally, the involvement of ASMase and ceramide has been
demonstrated in many of these infectious states, including infec-
tions with N. gonorrhoea, P. aeruginosa, S. aureus, Rhinovirus and
Sindbis virus. CRP formation, however, has only been deﬁnitively
demonstrated in the cases of P. aeruginosa and Rhinovirus [127].
Involvement of CRPs in at least some aspects of infection with
pathogens, such as pathogen internalization, virus budding and
phagosome maturation, lysis and fusion, is most likely mediated
by ceramide’s ability to induce membrane curvature, leading to
membrane fusion/ﬁssion, as described above.
Finally, CRPs can function by regulating formation of membrane
channels. As demonstrated following infection with P. aeruginosa,
ASMase activation generates CRPs, which serve as sites into which
cystic ﬁbrosis transmembrane conductance regulator (CFTR) chlo-
ride channels insert, oligomerize and become functional [94]. Fur-
ther, the ability of ceramide to form pores in membranes of
intracellular organelles, opens up a possibility that CRP formation
is not restricted to the plasma membrane. As previously noted,
Colombini and co-workers argued that ceramide forms channels
in isolated mitochondria, leading to increased permeability of
mitochondrial outer membrane to cytochrome c, a crucial commit-
ment step in the intrinsic apoptotic pathway signaling cascade
[54–56]. Whether CRPs are involved in this process, however, re-
mains to be explored.
The properties of CRPs indicate that they possess a general func-
tion in signal transduction for a variety of stimuli. This theory is
also supported by the fact that CRPs are formed in response to avariety of somewhat unrelated cellular stimuli (see Table 1). How-
ever, it is not clear whether CRPs form in all cell types, nor whether
every stimulus that activates ASMase and/or induces ceramide ele-
vation leads to CRP formation. As CRP formation has not been stud-
ied in each instance where ASMase is activated, further
investigation is necessary to better understand the link between
the two processes.
The outcome of CRP formation in cells depends on the stimulus
that leads to their generation. For example, TNF-receptor super-
family members CD40 and Fas both lead to formation of CRPs in
JY B lymphocytes [104,118]. These receptors localize within CRPs,
leading to downstream activation of molecules that associate with
the receptor and the cognate signal transduction cascade, however
signaling is very different in the two instances. While Fas-induced
CRP formation leads to DISC complex generation and ultimately
apoptosis [104], CD40 engagement results in a pro-survival cas-
cade mediated by engagement of the MAPK signaling pathway
and IL-12 release, ultimately leading to B-cell activation. Both of
these processes are CRP-dependent and impaired in ASMase null
cells. These phenomena further suggest that CRPs play a general
function in transmembrane signal transduction [118].
The explanation as to why ASMase activation and CRP forma-
tion occur in response to certain stimuli in some cell types, but
not in others, remains unknown. For example, CRP formation has
been demonstrated in endothelial cells and hepatocytes stimulated
by IR and FasL. While endothelial cells form CRPs in response to
both of these stimuli, hepatocytes form CRPs in response to Fas
engagement but not IR. This ﬁnding is conﬁrmed by the cellular
outcomes in these two cell types. While endothelial cells treated
with IR and FasL undergo ceramide-dependent apoptosis, apopto-
sis is only observed in hepatocytes stimulated by FasL, as hepato-
cytes appear radioresistant. The reason for these observations has
not been elucidated, however it is clear that additional, cell speciﬁc
signals are needed for CRP formation, pre-requisite for full cellular
responses to speciﬁc stimuli.
4. Manipulation of CRPs in disease treatment
At present no drugs exist that speciﬁcally target CRPs to either
prevent or amplify their function. Nevertheless, data generated
from a number of groups suggests that CRPs mediate diverse dis-
ease pathologies and are engaged in disease treatment, summa-
rized in Table 2. While, CRP generation has not been directly
demonstrated in each of these disease states, primarily due to
technical constraints of visualizing CRPs in vivo, ASMase and in
some instances ceramide synthase have been shown to directly
mediate aspects of disease processes, pointing to likely involve-
ment of CRPs. Due to space constraints, however, we will focus
only on diseases where involvement of CRPs has been experimen-
tally shown or strongly suggested, namely vascular disorders, met-
abolic disorders and infectious diseases. We hence propose that
development of drugs that prevent or amplify the function of CRPs
might lead to novel therapies for these diseases.
Vascular dysfunction mediated by ASMase-generated ceramide
has been characterized for a number of stimuli, including platelet-
activating factor (PAF) and IR. Goggel et al. showed that PAF-in-
duced pulmonary edema is regulated, in part, by activating ASMase
in pulmonary microvessels, leading to elevated ceramide levels,
which in turn induce vascular leakage and pulmonary edema in
mice [79]. PAF-induced pulmonary edema was reduced in asm-
ase/mice and in wild-type littermates treated with the non-spe-
ciﬁc ASMase inhibitors xanthogenate D609 or imipramine, as well
as with a monoclonal anti-ceramide IgM antibody [79]. Although
ASMase-generated CRPs were not documented in this model,
attenuation of PAF-induced edema by exogenously-added anti-
body suggests that ceramide is indeed generated on the outer
Table 1
Ceramide-rich platform formation in biological systems.
Stimulus Cell type Cellular outcome Reference
FasL, CH 11 Jurkat T lymphocytes
JY B cell lymphocytes
H9 (human T cells)
SKW 6.4 cells (human B lymphocytes)
K50 cells (Burkitt lymphoma cells)
WI 38 Cells (human lung ﬁbroblasts)
H9 T cell lymphoma human PBLa
Murine granulosa cellsa
Lung epithelial cells
Murine and human lymphocytesa
Murine splenocytes and hepatocytesa
Coronary artery
Endothelial cellsa
Apoptosis [69,71,106,111,135–138]
TNFa Coronary artery endothelial cellsa Apoptosis [136]
Endostatin Coronary artery endothelial cellsa Apoptosis [136,139]
CD40L JY B lymphocytes
Human aortic endothelial cellsa
Activation [72,118]
[140]
Rituximab (CD20) Daudi cells (Burkitt lymphoma)
RL cells (follicular lymphoma)
Chronic lymphocyte leukemia (CLL)
cellsa
Growth inhibition [98]
TRAIL Murine T splenocytesa
BJAB cells (Burkitt lymphoma)
A549 (non-small cell epithelial lung
carcinoma)
L929 cells (murine aneuploid
ﬁbrosarcoma)
Apoptosis [73]
UV-C U937 Cells (human myeloblastoma)
Jurkat T lymphocytes
Apoptosis [81,82]
IR Jurkat T lymphocytes
Bovine aortic endothelial cellsa
SCC61 cells (head and neck squamous
carcinoma)
Apoptosis (Zhang and Kolesnick, unpublished)
(Stancevic and Kolesnick,
unpublished)
[110]
P. aureginosa Human nasal epithelial cellsa
Chang conjuctive epithelial cells
Murine tracheal epithelial cells (in vivo)
Murine lung ﬁbroblastsa
WI-38 cells (human lung ﬁbroblasts)
Alveolar macrophagesa
Apoptosis
Internalization
IL-1b release
[94,141]
Rhinovirus Chang epithelial cells
Murine nasal cellsa
Apoptosis
Internalization
[96,142]
Cisplatin HT29 Cells (colon carcinoma) Apoptosis [87]
Etoposide Bovine aortic endothelial cellsa
Human coronary artery endothelial
cellsa
Apoptosis (Jacobi and Haimovitz-Friedman,
unpublished)
Cytolytic T-cells Murine hepatocytes and splenocytesa Apoptosis [132]
ROS Peripheral blood neutrophilsa Apoptosis [135]
Anti-FCcRII antibody U937 (monocytic cells) FCcRII phosphorylation [103]
Anti-tumor ether lipid (ET-18-OCH3) Jurkat T lymphocytes
HL-60 Cells
Apoptosis [143]
Cu2+ treatment Murine hepatocytesa Apoptosis [92]
Ceramide (CD14 engagement) Monocytesa Innate immune [77]
Endotoxin (LPS) THP-1 cells (human acute
promonocytic leukemia)
TNFa production [144]
Oxotremorine (muscarinic type 1
receptor agonist)
Bovine coronary arterial myocytes
(CAMs)a
Production of cADPR and coronary artery
constriction
[145]
a Primary cells.
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studies indicate that ceramide derivatives are markedly elevated in
bronchoalveolar lavage ﬂuid in patients with acute respiratory dis-
tress syndrome, also known as ARDS. Further, plasma ceramide is
increased in sepsis patients, the principle inducer of ARDS, corre-
lating with mortality [128]. Collectively, these studies provide abasis for a new therapeutic approach identifying ASMase, cera-
mide, and presumably CRPs as potential targets in treatment of
acute lung injury (ALI).
Ceramide-mediated vascular dysfunction induced by IR and the
therapeutic potential of engaging this phenomenon were demon-
strated in solid tumors and the gastrointestinal (GI) tract.
Table 2
Conditions in which ASMase and ceramide-rich platforms play a role in pathophy-
siology or disease treatment.
Disease Reference
Vascular
disorders
PAF, TNF-induced pulmonary edema
(ALI)
[79]
IR-induced tumor vascular dysfunction [129]
GI syndrome [90]
Ischemic stroke [146]
Atherosclerosis [147]
Chronic heart failure [148]
Metabolic
disorders
Wilson’s disease [92]
Diabetesa [149–151]
Cancer Cancer chemotherapy (daunorubicin,
cisplatin, gemcitabine)
[87,88,152,153]
IR- and chemotherapy-induced side
effects (GVHD, infertility)
[89,131,132]
Infections Pseudomonas aureginosa [94]
Rhinovirus [96]
Sindbis virus [97]
Neisseriae gonorrhoea [93]
Staphylococcus aureus [154]
Sepsis [155]
Lung diseases Cystic ﬁbrosis [133]
Emphysemaa [156]
Liver disease Autoimmune hepatitis [157]
Central
nervous
system
Alzheimer’s disease [158]
a Ceramide synthase has also been shown to be involved in generation of cera-
mide that mediates these pathologies.
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lethality after exposure to single high-dose radiotherapy, an
emerging therapeutic modality, is conditionally linked to an early
and massive wave of ASMase-mediated apoptosis in the microvas-
cular endothelium of exposed tissue [129]. These studies further
showed that early-phase microvascular endothelial apoptotic in-
jury is mandatory for tumor cure, as MCA/129 ﬁbrosarcomas
grown in asmase/mice, which provide apoptosis resistant vascu-
lature, were completely resistant to the curative effects of up to
15 Gy IR, a dose that normally induces 50% cure of tumor im-
planted into wild-type littermates [129]. Although direct proof
for CRP involvement in the tumor response to IR in this system is
still lacking, due to technical problems, preliminary studies from
our laboratory demonstrate CRP formation in an isolated popula-
tion of tumor endothelium irradiated ex vivo (Stancevic and Kole-
snick, unpublished). These data highlight the importance of CRPs in
microvascular cellular responses to IR, in particular in endothelial
cell apoptotic death. Along these lines, restoring or amplifying
CRP formation in the endothelium may radiosensitize tumors. In
fact, recent in vivo data by Smith et al. demonstrated that local
generation of ceramide in tumors, achieved through administra-
tion of recombinant ASMase (rhASM), acts synergistically with IR,
leading to a threefold decrease in tumor size [130]. The authors
provide evidence that the endothelial compartment mediates the
tumor response to IR enhanced by rhASM administration, as a sig-
niﬁcant decrease in the number of endothelial vessels per micro-
scopic ﬁeld of treated tumors was documented [130]. Taken
together these studies suggest that amplifying CRP generation in
tumor microvasculature via increasing ASMase-mediated cera-
mide generation represents a promising therapeutic strategy
requiring further development.
As with tumor tissue, the endothelial-stem cell linkage mecha-
nism was shown to mediate normal tissue damage after single
high-dose IR exposure in the GI tract. The lethal GI syndrome not
only limits the efﬁcacy of IR in cancer therapy, but also presents
a potential threat as a result of whole body irradiation in otherclinical contexts, such as a nuclear accident. In the murine small
intestines, IR-induced GI toxicity is mediated by a wave of micro-
vascular endothelial apoptosis within the lamina propria, which
regulates survival of IR-injured crypt SCCs. As in tumor, endothelial
apoptotic injury in the GI tract is mediated by ASMase, as genetic
or pharmacologic inactivation of ASMase conferred resistance to
IR-induced microvascular apoptosis and, in turn, SCC lethality, pre-
serving the GI tract and leading to animal survival [90]. These stud-
ies suggest a potential approach to protect the GI tract from IR
lethality by decreasing ceramide levels, leading to an increase in
the therapeutic index during cancer treatment of organs in the
abdomen and prevention of a lethal GI syndrome resulting from to-
tal body irradiation in cases as extreme as a radiological terrorist
attack.
In addition to the GI tract, reduction of ceramide levels may
protect other tissues from the side effects of cancer therapies,
namely oocytes and tissues affected during acute graft-versus-host
disease (GVHD). Published data indicate that chemotherapy- and
IR-induced apoptosis of oocytes may be mediated by ASMase and
its second messenger ceramide. Speciﬁcally, Tilly and colleagues
demonstrated that oocytes lacking ASMase are resistant to doxoru-
bicin-induced apoptosis in vitro. Further, administration of sphin-
gosine-1-phosphate (S1P), a ceramide metabolite, which counteracts
ceramide’s pro-apoptotic effects, inhibits apoptosis induced by
anti-cancer therapy in vivo. In these studies, IR-induced oocyte loss
in adult wild-type female mice, the event that drives premature
ovarian failure and infertility in female cancer patients, was com-
pletely prevented by injection of S1P into the ovary just prior to
IR [89]. Additionally, mating trials of wild-type mice subjected to
IR treatment showed that preservation of oocytes by S1P pretreat-
ment leads to an increase in pregnancy rates from 12.5% to 75%
[131]. More importantly, this preservation of fertility was accom-
plished without propagating genetic damage in the offspring of
S1P-treated irradiated females. These data collectively demon-
strate that preservation of ovarian function and fertility post-irra-
diation can be safely and effectively achieved in vivo using S1P,
providing a basis for the development of S1P-based therapies for
the treatment of infertility.
GVHD is a common complication of allogeneic bone marrow
transplantation mediated by cytotoxic T lymphocyte (CTL)-in-
duced apoptosis leading to host organ damage. Rotolo et al. re-
cently showed that ASMase is involved in development and
progression of acute GVHD. Using clinically-relevant mouse mod-
els of acute GVHD in which allogeneic bone marrow and T cells
were transplanted into wild-type and asmase/ hosts, the authors
identiﬁed host ASMase as critical for full blown GVHD. More spe-
ciﬁcally, the mechanism by which ASMase mediates CTL-induced
apoptosis of target cells (hepatocytes, small and large intestinal
epithelium and endothelium, skin) appeared to require CRP forma-
tion on target cell membranes [132]. The lack of host ASMase, and
in turn abrogation of CRP formation (deﬁned using an ex vivo 2 cell
model of GVHD in which in vivo-activated T cell effector cells were
coincubated with asmase+/+ or asmase/ hepatocyte target cells),
attenuated organ injury and consequent cytokine storm, decreas-
ing morbidity and mortality. These ﬁndings, delineating a require-
ment for target cell ASMase in evolution of GVHD, provide
potential new targets for disease management through inhibition
of CRPs and/or ASMase activity.
Wilson’s disease is a metabolic disorder in which impaired he-
patic secretion of Cu2+ results in its inappropriate accumulation
within the liver parenchyma, and ultimately cirrhosis and hemo-
lytic anemia. Recent studies by Lang et al. showed that Cu2+-trig-
gered hepatocyte apoptosis is mediated by ASMase activation,
ceramide release and subsequent CRP formation [92]. Genetic deﬁ-
ciency or pharmacologic inhibition of ASMase by amitriptyline, and
presumably abrogation of CRP formation, prevented Cu2+-induced
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Wilson’s disease from acute hepatocyte injury, liver failure and
early death. Furthermore, these studies indicated a novel mecha-
nism for Cu2+-mediated anemia in which Cu2+-triggered secretion
of ASMase from leukocyte results in ceramide formation in eryth-
rocytes and subsequent exposure of phosphatidylserine at the cell
surface. In vivo, phosphatidylserine exposure led to immediate
clearance of affected erythrocytes from blood, an event absent in
asmase/ animals. Speciﬁcally, erythrocytes in asmase/ mice
were resistant to Cu2+ treatment, failing to elevate ceramide and
expose phosphatidylserine, and hence avoided in vivo elimination.
The relevance of this model was shown in human subjects, as pa-
tients with Wilson’ disease exhibited elevated plasma levels of
ASMase and displayed constitutively increased ceramide- and
phosphatidylserine-positive erythrocytes [92]. Hence, these data
indicate the signiﬁcance of ceramide and CRPs for pathogenesis
of Wilson’s disease, and provide a basis for treatment by pharma-
cologic inhibition of ASMase and/or CRP formation.
Inhibition of infectious diseases by manipulation of ceramide
metabolism presents another area with exciting therapeutic poten-
tial. As noted previously, CRPs appear involved in many aspects of
infection with various pathogens – internalization of pathogen,
activation of intracellular signaling pathways, induction of host cell
death, and cytokine release, to name a few. As demonstrated by
Grassme and colleagues, CRPs are critical for internalization of
P. aeruginosa into epithelial cells and ﬁbroblasts, induction of apop-
tosis in the infected cell and regulation of host cell cytokine release
(the innate immune response) [94]. CRP formation seemed re-
quired for infection, as pharmacologic (sphingolipid raft disrupting
agents – ﬁlipin, nystatin or b-cyclodextrin) or genetic (ASMase
null) inhibition of CRP formation in lung epithelial cells correlated
with a failure to internalize bacteria and lack of apoptosis of in-
fected cells in vitro and in vivo. Additionally, CRP formation was
shown to mediate the host defense against the acute P. aeruginosa
infection. Speciﬁcally, inhibition of CRP formation in ASMase null
mice led to an eightfold increase in IL-1b release and IL-1-mediated
septic death of these mice. Addition of C16-ceramide led to restora-
tion of CRP formation, bacterial internalization and epithelial cell
apoptosis, as well as normalization of IL-1b release in cultured lung
epithelial cells. These data indicate ASMase-generated ceramide
and CRPs may play a central role in both P. aeruginosa infection,
as well as the host defense against the pathogen, making ASMase
a potential, but complicated therapeutic target.
In fact, recent ﬁndings by Gulbins and co-workers suggest that
careful titration of ASMase activity to normalize chronically-ele-
vated ceramide levels in affected lungs of cystic ﬁbrosis patients
may provide a therapeutic advantage in treatment of chronic
P. aeruginosa infection [133]. The concept here would be to titrate
ceramide back to physiologic levels but not further to avoid the sce-
nario described above regarding the uncontrolled innate immune
response. Cystic ﬁbrosis is caused by mutations in the transmem-
brane conductance regulator (CFTR) and is characterized by chronic
lung inﬂammationand frequent chronic lung infectionswithP. aeru-
ginosa, Burkholderia cepacia and Haemophilus inﬂuenzae. The molec-
ular mechanism responsible for pulmonary inﬂammation and high
susceptibility to infection has been recently revealed by Teichgraber
et al. In their studies,CFTRdeﬁciencyresulted inalkalizationof intra-
cellular vesicles in epithelial cells that contain ASMase and acid cer-
amidase. While an increase in the pH to 6.0 completely inactivates
acid ceramidase, it decreases the activity of ASMase only by 30–
40%, resulting in an imbalance between ASMase cleavage of SM to
ceramide and acid ceramidase consumption of ceramide [133]. Con-
sistent with these observations, ceramide accumulation was de-
tected in respiratory epithelial cells and submucosal glands in
CFTR-deﬁcient mice, as well as in lung specimens and nasal epithe-
lial cells from patients with cystic ﬁbrosis. As demonstrated byTeichgraber et al., ceramide accumulation leads to chronic respira-
tory epithelial cell death by apoptosis and release of DNA into bron-
chi, where it serves as an adhesin for P. aeruginosa resulting in high
susceptibility to persistent infection. Pharmacologic treatment of
CFTR-deﬁcient mice with amitriptyline or partial genetic deﬁciency
of ASMase (haploinsufﬁciency) normalized pulmonary ceramide
concentrations and prevented all pathologic effects, including the
susceptibility to infection. These ﬁndings suggest that inhibition of
ASMaseandnormalizationof ceramide levelsmightbe anewimpor-
tant treatment strategy to prevent and treat bacterial infections in
cystic ﬁbrosis patients, a concept currently being tested in Phase II
trials in Germany [134].
5. Conclusion
In summary, accumulating evidence indicates that the unique
biophysical properties of ceramide dictate its biological function
through membrane reorganization and formation of CRPs. CRPs
form in response to diverse stimuli and represent novel sites of sig-
nal transduction initiation and transmission across the plasma
membrane. Crucial involvement of CRPs in a number of disease ini-
tiation states, as well as disease treatments, makes them an attrac-
tive therapeutic target. Speciﬁcally, strategies for increasing CRP
formation in tumor vasculature may potentially sensitize tumors
to curative effects of IR and chemotherapy. Alternately, attenuation
of CRP formation could potentially inhibit lethal side effects of can-
cer therapies, such as GI syndrome and GVHD, increasing the ther-
apeutic index. Additionally, the central role of CRPs in infection of
mammalian cells with at least some pathogenic bacteria, suggests
their manipulation as a strategy to alter infection, particularly in
highly susceptible individuals, such as cystic ﬁbrosis patients.
Overall, identiﬁed less than a decade ago, CRPs still represent novel
signaling structures, the biomedical importance of which is just
starting to be revealed. As such, further research in this largely un-
tapped ﬁeld will undoubtedly identify involvement of CRPs in
many more processes, and more clearly elucidate how these enig-
matic structures are capable of transferring speciﬁc information
regarding diverse stresses.
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